Blood filtering vs. antibody therapy: new hope for nerve disorder patients
NCT ID NCT04881682
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two treatments for CIDP, a nerve condition that causes weakness and numbness. It involves 20 adults who did not get better with steroids. One group receives a blood-filtering procedure called immunoadsorption, and the other receives standard antibody infusions. The goal is to see which approach better controls the disease and improves muscle strength and daily function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIDP are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Neurology, University of Ulm
RECRUITINGUlm, Baden-Wurttemberg, 89081, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ultrasound and blood markers may unlock personalized treatment for rare nerve disease
- New hope for teens with rare nerve disease: drug trial launches
- New hope for CIDP patients: early access to efgartigimod drug
- Body fat may change how well immune therapy works
- New study tracks Efgartigimod's Real-World impact on CIDP patients
- New drug could replace standard infusions for nerve disorder